Hot Investor Mandate: VC/PE Firm Based in the US Invests Up to $15M With Strongest Interests in Therapeutics, and Platform Technologies

26 Jan

A venture capital/private equity firm based in the US invests in both digital health technologies and the life sciences. For their life sciences investments, most of them are in therapeutics, with about 5% of their investments going to life science tools and diagnostics. For therapeutics companies, the firm prefers to see efficacy and safety data before investing. For tools, diagnostics and digital health companies, the companies should be either revenue generating, or, at minimum, revenue in sight. The firm will consider global opportunities, but invests primarily in the US, and generally invests 5-15M in their early stage deals.

For therapeutics companies, the firm is modality and indication agnostic, although is less interested in microbiotic-related therapeutics. The firm prefers platform technologies, or an associative program; they do not invest in single assets. For digital health companies, the firm invests primarily in enterprise software, such as clinical data management, tools to enable better care and healthcare IT companies.

The firm generally leads or co-leads investments, and will take a board seat after investing. For therapeutics companies, the firm prefers the startups to have raised 1-5M in a previous round before investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: